Logo

Gijsbertus Pronk

Feb 27, 2004
Premium

Private biotechnology company Serenex said this week that it has hired Gijsbertus Pronk as its director of biology.

Pronk formerly was director of research and business development at Atugen, where he managed the company’s North American customer collaborations and supported internal research and development programs, said Serenex.

 

Filed under

Gene Silencing/Gene Editing
RNAi
Breaking News
The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.